Literature DB >> 33567745

The Ratio of RAC1B to RAC1 Expression in Breast Cancer Cell Lines as a Determinant of Epithelial/Mesenchymal Differentiation and Migratory Potential.

Caroline Eiden1, Hendrik Ungefroren1,2.   

Abstract

Breast cancer (BC) is a heterogenous disease encompassing tumors with different histomorphological phenotypes and transcriptionally defined subtypes. However, the non-mutational/epigenetic alterations that are associated with or causally involved in phenotype diversity or conversion remain to be elucidated. Data from the pancreatic cancer model have shown that the small GTPase RAC1 and its alternatively spliced isoform, RAC1B, antagonistically control epithelial-mesenchymal transition and cell motility induced by transforming growth factor β. Using a battery of established BC cell lines with either a well-differentiated epithelial or poorly differentiated mesenchymal phenotype, we observed subtype-specific protein expression of RAC1B and RAC1. While epithelial BC lines were RAC1Bhigh and RAC1low, mesenchymal lines exhibited the reverse expression pattern. High RAC1B and/or low RAC1 abundance also correlated closely with a poor invasion potential, and vice versa, as revealed by measuring random cell migration (chemokinesis), the preferred mode of cellular movement in cells that have undergone mesenchymal transdifferentiation. We propose that a high RAC1B:RAC1 ratio in BC cells is predictive of an epithelial phenotype, while low RAC1B along with high RAC1 is a distinguishing feature of the mesenchymal state. The combined quantitative assessment of RAC1B and RAC1 in tumor biopsies of BC patients may represent a novel diagnostic tool for probing molecular subtype and eventually predict malignant potential of breast tumors.

Entities:  

Keywords:  RAC1; RAC1B; breast cancer; chemokinesis; diagnostic marker; epithelial subtype; invasion; mesenchymal; migration; phenotype

Year:  2021        PMID: 33567745      PMCID: PMC7915250          DOI: 10.3390/cells10020351

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  28 in total

1.  EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration.

Authors:  Nicole M Aiello; Ravikanth Maddipati; Robert J Norgard; David Balli; Jinyang Li; Salina Yuan; Taiji Yamazoe; Taylor Black; Amine Sahmoud; Emma E Furth; Dafna Bar-Sagi; Ben Z Stanger
Journal:  Dev Cell       Date:  2018-06-18       Impact factor: 12.270

2.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

3.  Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling.

Authors:  Paulo Matos; John G Collard; Peter Jordan
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

4.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

5.  Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Authors:  Eric A Collisson; Anguraj Sadanandam; Peter Olson; William J Gibb; Morgan Truitt; Shenda Gu; Janine Cooc; Jennifer Weinkle; Grace E Kim; Lakshmi Jakkula; Heidi S Feiler; Andrew H Ko; Adam B Olshen; Kathleen L Danenberg; Margaret A Tempero; Paul T Spellman; Douglas Hanahan; Joe W Gray
Journal:  Nat Med       Date:  2011-04-03       Impact factor: 53.440

6.  c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.

Authors:  Longquan Lou; Ziyi Yu; Yue Wang; Shui Wang; Yi Zhao
Journal:  Cancer Sci       Date:  2018-04-17       Impact factor: 6.716

Review 7.  Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.

Authors:  Fangyuan Shao; Heng Sun; Chu-Xia Deng
Journal:  Oncotarget       Date:  2017-08-16

Review 8.  RAC1B: A Rho GTPase with Versatile Functions in Malignant Transformation and Tumor Progression.

Authors:  Catharina Melzer; Ralf Hass; Hendrik Lehnert; Hendrik Ungefroren
Journal:  Cells       Date:  2019-01-04       Impact factor: 6.600

9.  Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan.

Authors:  Hannah Otterbein; Hendrik Lehnert; Hendrik Ungefroren
Journal:  Cancers (Basel)       Date:  2019-12-06       Impact factor: 6.639

Review 10.  The Small GTPase RAC1B: A Potent Negative Regulator of-and Useful Tool to Study-TGFβ Signaling.

Authors:  Hendrik Ungefroren; Ulrich F Wellner; Tobias Keck; Hendrik Lehnert; Jens-Uwe Marquardt
Journal:  Cancers (Basel)       Date:  2020-11-22       Impact factor: 6.639

View more
  4 in total

Review 1.  Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives.

Authors:  Harishini Rajaratinam; Noor Fatmawati Mokhtar; Nurul Asma-Abdullah; Wan Ezumi Mohd Fuad
Journal:  Biomolecules       Date:  2022-02-15

2.  The Quasimesenchymal Pancreatic Ductal Epithelial Cell Line PANC-1-A Useful Model to Study Clonal Heterogeneity and EMT Subtype Shifting.

Authors:  Hendrik Ungefroren; Isabel Thürling; Benedikt Färber; Tanja Kowalke; Tanja Fischer; Leonardo Vinícius Monteiro De Assis; Rüdiger Braun; Darko Castven; Henrik Oster; Björn Konukiewitz; Ulrich Friedrich Wellner; Hendrik Lehnert; Jens-Uwe Marquardt
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

3.  Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.

Authors:  Ailed Cruz-Collazo; Jean F Ruiz-Calderon; Hector Picon; Luis D Borrero-Garcia; Irmaris Lopez; Linette Castillo-Pichardo; Maria Del Mar Maldonado; Jorge Duconge; Julia I Medina; Marvin J Bayro; Eliud Hernández-O'Farrill; Cornelis P Vlaar; Suranganie Dharmawardhane
Journal:  Mol Cancer Ther       Date:  2021-10-04       Impact factor: 6.009

4.  A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.

Authors:  Jamal Elhasnaoui; Giulio Ferrero; Valentina Miano; Lorenzo Franchitti; Isabella Tarulli; Lucia Coscujuela Tarrero; Santina Cutrupi; Michele De Bortoli
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.